Guardiola Philippe, Socié Gérard, Li Xiaxin, Ribaud Patricia, Devergie Agnés, Espérou Hélène, Richard Patrice, Traineau Richard, Janin Anne, Gluckman Eliane
Service d'Hématologie--Greffe de Moelle "Trèfle 3," Hôpital Saint Louis, Paris, France.
Blood. 2004 Jan 1;103(1):73-7. doi: 10.1182/blood-2003-06-2146. Epub 2003 Aug 28.
To assess whether Fanconi anemia (FA) patients might be at risk for acute graft-versus-host disease (AGvHD) despite using low-intensity conditionings, we retrospectively analyzed the incidence of AGvHD and its impact on outcome in 37 FA patients and 73 patients with acquired aplastic anemia (AAA) that received transplants at Saint Louis Hospital from HLA-genotypic identical siblings with similar conditionings (thoraco-abdominal irradiation plus cyclophosphamide 20 [FA] or 150 mg/kg [AAA]). Despite being younger, FA patients had an increased risk of grades II to IV AGvHD (relative risk [RR], 2.00; P =.021), especially in younger patients (RR, 7.93; P =.014). The risks of requiring systemic corticosteroids to treat AGvHD and experiencing cortico-resistant AGvHD were significantly increased in FA patients. Although non-FA and FA patients had similar 10-year outcomes, acute and chronic GvHD had a biphasic effect on FA patient outcome with an additional cluster of lethal events starting by 5 years after transplantation. This late survival fall, restricted to FA patients, was closely related to head and neck carcinomas (15-year incidence: 53%). FA patients represent a group at risk regarding AGvHD when using irradiation-based conditionings. The impact of AGvHD on survival may not be limited to the early posttransplantation period and may be a major risk factor for head and neck carcinomas and late mortality in FA patients.
为评估范可尼贫血(FA)患者即便采用低强度预处理是否仍有发生急性移植物抗宿主病(AGvHD)的风险,我们回顾性分析了37例FA患者和73例获得性再生障碍性贫血(AAA)患者发生AGvHD的发生率及其对预后的影响,这些患者在圣路易斯医院接受了来自 HLA 基因型相同的同胞的移植,预处理方案相似(胸腹部照射加环磷酰胺20 [FA] 或150 mg/kg [AAA])。尽管FA患者年龄较小,但发生Ⅱ至Ⅳ级AGvHD的风险增加(相对风险[RR],2.00;P = 0.021),尤其是年轻患者(RR,7.93;P = 0.014)。FA患者使用全身性皮质类固醇治疗AGvHD以及发生皮质类固醇抵抗性AGvHD的风险显著增加。尽管非FA患者和FA患者的10年预后相似,但急性和慢性移植物抗宿主病对FA患者的预后有双相影响,移植后5年开始出现另一组致死性事件。这种仅限于FA患者的晚期生存率下降与头颈癌密切相关(15年发病率:53%)。在使用基于照射的预处理方案时,FA患者是发生AGvHD的风险群体。AGvHD对生存的影响可能不仅限于移植后早期,可能是FA患者发生头颈癌和晚期死亡的主要危险因素。